ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0330

Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors

Timothy Kwok1, Mitchell Sutton2, Daniel Pereira2, Vinod Chandran3 and Dafna Gladman3, 1University of Toronto, Toronto, ON, Canada, 2Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

Meeting: ACR Convergence 2020

Keywords: Epidemiology, Psoriatic arthritis, surgery

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Despite optimal medical therapy, joint space disease and skeletal damage persists in a subset of patients with PsA, many of whom requiring musculoskeletal (MSK) surgery for disease related morbidity. The purpose of this study was to determine the prevalence of MSK surgery in PsA patients, describe the type/indications for surgery and associated risk factors that increase the likelihood of undergoing MSK surgery.

Methods: A longitudinal single center cohort was analyzed to identify PsA patients who had MSK surgery from January 1973 to December 2019 inclusive. All cohort patients fulfilled the 2006 CASPAR criteria. Data from all MSK surgeries were collected using a web-based database. Patient charts were reviewed to confirm individual surgeries were MSK related and attributable to PsA by cross-referencing to clinical records and pre and post-operative diagnoses. Descriptive statistics determined the prevalence of MSK surgeries attributable to PsA, in addition to categories, indications and anatomical locations for surgery. A cox proportional-hazards model determined predictors at initial clinic visit for undergoing first MSK surgery. Lastly, a cox proportional-hazards model using time-dependent covariates evaluated the cumulative effect of PsA disease burden on undergoing MSK surgery. All models were adjusted for sex, age and duration of PsA at baseline.

Results: Of the 1574 patients in the cohort, 185 patients had 379 MSK surgeries related to PsA (Table 1). Common surgeries were arthrodesis (27%) and arthroplasty (27%). Common anatomical locations included the knee (28%) and finger (21%) with surgical indications representing deformities (42%) and inflammation/synovitis (42%). 59% of surgeries were joint sacrificing while 41% were joint retaining. Complete covariate data for the cox proportional-hazards model at initial clinic visit and the time-dependent covariate cox proportional-hazards model was present in 97 and 90 patients respectively. At baseline visit, higher age (hazard ratio, 1.043; p< 0.001) and total damaged joints (hazard ratio 1.047, p< 0.001) were predictors for undergoing first MSK surgery (Table 2). In time-dependent covariate analysis, biologic use (hazard ratio 2.890, p< 0.001), nonsteroidal anti-inflammatory drug (NSAID) use (hazard ratio 2.623, p< 0.001), the presence of nail lesions (hazard ratio 2.482, p< 0.001), higher age at baseline visit (hazard ratio 1.073, p< 0.001) and higher total actively inflamed joint count (hazard ratio 1.032, p< 0.002) were predictors for undergoing first MSK surgery (Table 3).

Conclusion: 11.8% of patients in our cohort had at least one MSK surgery attributable to PsA, with most surgeries being joint sacrificing in nature (59%). Older age at presentation and more severe disease evidenced by damaged joints at presentation, active inflammation, nail lesions and use of biologic therapy were associated with a higher risk of MSK surgery. Despite medical therapy, a significant number of patients still require surgical intervention for mainly deformities (42%) or inflammation/synovitis (42%).

Table 1. Distribution and descriptions of MSK surgeries performed attributable to PsA (n=379)

Table 2: Multivariate cox proportional-hazards model for predictors at initial clinic visit of undergoing first MSK surgery adjusted for sex, age and duration of PsA at baseline

Table 3: Multivariate cox proportional-hazards model using time-dependent covariates for predictors of undergoing first MSK surgery adjusted for sex, age and duration of PsA at baseline


Disclosure: T. Kwok, None; M. Sutton, None; D. Pereira, None; V. Chandran, Abbvie, 2, 5, Amgen, 2, 5, Celgene, 2, 5, Eli Lilly, 5, Eli Lilly, 3, Janssen, 8, Novartis, 5, Pfizer, 5, UCB, 5; D. Gladman, AbbVie, 2, 5, Amgen, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5, Bristol-Myers Squibb, 5, Gilead, 5, Galapagos, 5, Celgene, 2, 5, Eli Lilly, 2, 5.

To cite this abstract in AMA style:

Kwok T, Sutton M, Pereira D, Chandran V, Gladman D. Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/musculoskeletal-surgery-in-psoriatic-arthritis-prevalence-and-risk-factors/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/musculoskeletal-surgery-in-psoriatic-arthritis-prevalence-and-risk-factors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology